Laser Immunotherapy: Novel Modality to Treat Cancer through Specific Antitumor Immune Response

Xiaosong Li; Wei R.

doi:10.3788/cjl20103711.2698

[1] L. M. Weiner. Monoclonal antibody therapy of cancer[J]. Semin. Oncol., 1999, 26(5 Suppl 14): 43～51

[2] J. H. Tanne. FDA approves prostate cancer “vaccine”[J]. BMJ, 2010, 340: c2431

[3] Z. Tabi, S. Man. Challenges for cancer vaccine development[J]. Adv. Drug. Deliv. Rev., 2006, 58(8): 902～915

[4] B. Bodey, B. Jr Bodey, S. E. Siegel et al.. Failure of cancer vaccines: the significant limitations of this approach to immunotherapy[J]. Anticancer Res., 2000, 20(4): 2665～2676

[5] W. R. Chen, R. L. Adams, R. Carubelli et al.. Laser-photosensitizer assisted immunotherapy: A novel modality in cancer treatment[J]. Cancer Lett., 1997, 115(1): 25～30

[6] W. R. Chen, A. K. Singhal, H. Liu et al.. Antitumor immunity induced by laser immunotherapy and its adoptive transfer[J]. Cancer Res., 2001, 61(2): 459～461

[7] W. R. Chen, S. W. Jeong, M. D. Lucroy et al.. Induced anti-tumor immunity against DMBA-4 metastatic mammary tumors in rats using a novel approach[J]. Int. J. Cancer., 2003, 107(6): 1053～1057

[8] W. R. Chen, R. Carubelli, H. Liu et al.. Laser immunotherapy: a novel treatment modality for metastatic tumors[J]. Mol. Biotechnol., 2003, 25(1): 37～43

[9] W. R. Chen, H. Liu, J. W. Ritchey et al.. Effect of different components of laser immunotherapy in treatment of metastatic tumors in rats[J]. Cancer Res., 2002, 62(15): 4295～4299

[10] M. Korbelik, I. Cecic. Enhancement of tumour response to photodynamic therapy by adjuvant mycobacterium cell-wall treatment[J]. J. Photochem. Photobiol. B, 1998, 44(2):151～158

[11] M. Uehara, K. Sano, Z. L. Wang et al.. Enhancement of the photodynamic antitumor effect by streptococcal preparation OK-432 in the mouse carcinoma[J]. Cancer Immunol. Immunother., 2000, 49(8): 401～409

[12] S. C. Mayo, T. M. Pawlik. Thermal ablative therapies for secondary hepatic malignancies[J]. Cancer J., 2010, 16(2): 111～117

[13] F. Zhou, D. Xing, Z. Ou et al.. Cancer photothermal therapy in the near-infrared region by using single-walled carbon nanotubes[J]. J. Biomed. Opt., 2009, 14(2): 021009

[14] Y. Chen, S. C. Gnyawali, F. Wu et al.. Magnetic resonance imaging guidance for laser photothermal therapy[J]. J. Biomed. Opt., 2008, 13(4): 044033

[15] W. C. Dooley, H. I. Vargas, A. J. Fenn et al.. Focused microwave thermotherapy for preoperative treatment of invasive breast cancer: a review of clinical studies[J]. Ann. Surg. Oncol., 2010, 17(4): 1076～1093

[16] B. P. Hung. The effect of high intensity focused ultrasound ablation of human breast cancer[J]. Surgery, 2010, 147(3): 466～467

[17] H. G. Zhang, K. Mehta, P. Cohen et al.. Hyperthermia on immune regulation: a temperature′s story[J]. Cancer Lett., 2008, 271(2): 191～204

[18] J. J. Crochet, S. C. Gnyawali, Y. Chen et al.. Temperature distribution in selective laser-tissue interaction[J]. J. Biomed. Opt., 2006, 11(3): 34031

[19] V. K. Todorova, V. S. Klimberg, L. Hennings et al.. Immunomodulatory effects of radiofrequency ablation in a breast cancer model[J]. Immunol. Invest., 2010, 39(1): 74～92

[20] F. Wu, L. Zhou, W. R. Chen. Host antitumour immune responses to HIFU ablation[J]. Int. J. Hyperthermia, 2007, 23(2): 165～171

[21] A. Zerbini, M. Pilli, D. Laccabue et al.. Radiofrequency thermal ablation for hepatocellular carcinoma stimulates autologous NK-cell response[J]. Gastroenterology, 2010, 138(5): 1931～1942

[22] Z. Hu, X. Y. Yang, Y. Liu et al.. Investigation of HIFU-induced anti-tumor immunity in a murine tumor model[J]. J. Transl. Med., 2007, 5: 34

[23] J. Gong, Y. Zhang, J. Durfee et al.. A heat shock protein 70-based vaccine with enhanced immunogenicity for clinical use[J]. J. Immunol., 2010, 184(1): 488～496

[24] B. H.Segal, X. Y. Wang, C. G. Dennis et al.. Heat shock proteins as vaccine adjuvants in infections and cancer[J]. Drug Discov. Today, 2006, 11(11-12): 534～540

[25] M. Nishikawa, S. Takemoto, Y. Takakura. Heat shock protein derivatives for delivery of antigens to antigen presenting cells[J]. Int. J. Pharm., 2008, 354(1-2): 23～27

[26] T. J. Yoon, J. Y. Kim, H. Kim et al.. Anti-tumor immunostimulatory effect of heat-killed tumor cells[J]. Exp. Mol. Med., 2008, 40(1): 130～144

[27] T. Torigoe, Y. Tamura, N. Sato. Heat shock proteins and immunity: application of hyperthermia for immunomodulation[J]. Int. J. Hyperthermia, 2009, 25(8): 610～616

[28] W. L. Yang, D. G. Nair, R. Makizumi et al.. Heat shock protein 70 is induced in mouse human colon tumor xenografts after sublethal radiofrequency ablation[J]. Ann. Surg. Oncol., 2004, 11(4): 399～406

[29] E. Jager, D. Jager, A. Knuth. Antigen-specific immunotherapy and cancer vaccines[J]. Int. J. Cancer, 2003, 106(6): 817～820

[30] W. R. Chen, M. Korbelik, K. E. Bartels et al.. Enhancement of laser cancer treatment by a chitosan-derived immunoadjuvant[J]. Photochem. Photobiol., 2005, 81(1): 190～195

[31] S. Song, F. Zhou, R. E. Nordquist et al.. Glycated chitosan as a new non-toxic immunological stimulant[J]. Immunopharmacol Immunotoxicol., 2009, 31(2): 202～208

[32] T. J. Stewart, S. I. Abrams. How tumours escape mass destruction[J]. Oncogene, 2008, 27(45): 5894～5903

[33] R. Kim, M. Emi, K. Tanabe. Cancer immunoediting from immune surveillance to immune escape[J]. Immunology, 2007, 121(1): 1～14

[34] F. H. Igney, P. H. Krammer. Immune escape of tumors: apoptosis resistance and tumor counterattack[J]. J. Leukoc. Biol., 2002, 71(6): 907～920

[35] M. F. Naylor, W. R. Chen, T. K. Teague et al.. In situ photo immunotherapy: a tumor-directed treatment modality for melanoma[J]. Br. J. Dermatol., 2006, 155(6): 1287～1292

[36] X. Li, M. F. Naylor, R. E. Nordquist et al.. Preliminary results of a phase Ⅰ/Ⅱ clinical trial using in situ photoimmunotherapy combined with imiquimod for metastatic melanoma patients[C]. SPIE, 2010, 7565: 756506

[37] T. Hode, M. C. Guerra, G. L. Ferrel et al.. Laser immunotherapy: initial results from a human breast cancer pilot trial[C]. SPIE, 2010, 7565: 756507

[38] A. Mukhopadhaya, J. Mendecki, X. Dong et al.. Localized hyperthermia combined with intratumoral dendritic cells induces systemic antitumor immunity[J]. Cancer Res., 2007, 67(16): 7798～7806

[39] J. Guo, J. Zhu, X. Sheng et al.. Intratumoral injection of dendritic cells in combination with local hyperthermia induces systemic antitumor effect in patients with advanced melanoma[J]. Int. J. Cancer, 2007, 120(11): 2418～2425

[40] A. P. Castano, P. Mroz, M. X. Wu et al.. Photodynamic therapy plus low-dose cyclophosphamide generates antitumor immunity in a mouse model[J]. Proc. Natl. Acad. Sci. USA, 2008, 105(14): 5495～5500

[41] C. L. Jr. Slingluff, G. R. Petroni, W. C. Olson et al.. Effect of granulocyte/macrophage colony-stimulating factor on circulating CD8+ and CD4+ T-cell responses to a multipeptide melanoma vaccine: outcome of a multicenter randomized trial[J]. Clin. Cancer Res., 2009, 15(22): 7036～7044

[42] E. S. Antonarakis, M. A. Carducci. Combining low-dose cyclophosphamide with GM-CSF-secreting prostate cancer immunotherapy enhances antitumor immune effects[J]. Expert Opin. Investig. Drugs, 2010, 19(2): 311～314